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Abstract
Background: The development of an HIV/AIDS vaccine has proven to be elusive. Because human vaccine trials have not yet
demonstrated efficacy, new vaccine strategies are needed for the HIV vaccine pipeline. We have been developing a new HIV
vaccine platform using a live enterovirus, coxsackievirus B4 (CVB4) vector. Enteroviruses are ideal candidates for
development as a vaccine vector for oral delivery, because these viruses normally enter the body via the oral route and
survive the acidic environment of the stomach.
Methodology/Principal Findings: We constructed a live coxsackievirus B4 recombinant, CVB4/p24(733), that expresses
seventy-three amino acids of the gag p24 sequence (HXB2) and assessed T cell responses after immunization of mice. The
CVB4 recombinant was physically stable, replication-competent, and genetically stable. Oral or intraperitoneal immunization
with the recombinant resulted in strong systemic gag p24-specific T cell responses as determined by the IFN-c ELISPOT
assay and by multiparameter flow cytometry. Oral immunization with CVB4/p24(733) resulted in a short-lived, localized
infection of the gut without systemic spread. Because coxsackieviruses are ubiquitous in the human population, we also
evaluated whether the recombinant was able to induce gag p24-specific T cell responses in mice pre-immunized with the
CVB4 vector. We showed that oral immunization with CVB4/p24(733) induced gag p24-specific immune responses in vector-
immune mice.
Conclusions/Significance: The CVB4/p24(733) recombinant retained the physical and biological characteristics of the
parental CVB4 vector. Oral immunization with the CVB4 recombinant was safe and resulted in the induction of systemic HIV-
specific T cell responses. Furthermore, pre-existing vector immunity did not preclude the development of gag p24-specific T
cell responses. As the search continues for new vaccine strategies, the present study suggests that live CVB4/HIV
recombinants are potential new vaccine candidates for HIV.
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Introduction
The development of an HIV/AIDS vaccine has proven to be
elusive in spite of research efforts spanning over a quarter century
[1–3]. Current vaccine candidates consist of DNA that encodes
HIV peptides or proteins, purified proteins or peptides, and
recombinant bacterial and viral vectors that express HIV
sequences [1,4,5,6]. In addition, combinations of these vaccine
candidates have been used in various prime-boost regimens.
Because human vaccine trials have not yet demonstrated efficacy
[7–10], new vaccine strategies are needed for the HIV pipeline.
Because HIV infection is a disease of the mucosal immune system
with systemic manifestations [11–13], new vaccine approaches
must induce both mucosal and systemic T and B cell responses.
Given that the gastrointestinal mucosa is the primary reservoir for
HIV replication [11,12], vaccine strategies must be able to target
the induction of HIV-specific antibody and T cell responses in the
gut. One approach to induce immunity in the gastrointestinal
mucosa is by oral delivery of suitable vaccines. A well-known
example of an effective vaccine capable of inducing immune
responses in the gastrointestinal mucosa and in the systemic
circulation after oral delivery, is the live attenuated Sabin vaccine
for poliomyelitis [14].
We have been developing a new HIV vaccine platform using a
live coxsackievirus B4 (CVB4) vector [15,16]. Like the poliovirus-
es, coxsackieviruses are small RNA viruses belonging to the genus
enterovirus of the family Picornaviridae [17]. Enteroviruses are
ideal candidates for development as vaccine vectors for oral
delivery, because these viruses normally enter the body via the oral
route and are able to survive the acidic environment of the
stomach [18]. We have identified a CVB4 variant that is avirulent
and immunogenic [16]; mice immunized with the avirulent CVB4
variant are protected when subsequently challenged with a
virulent variant. The avirulent CVB4 variant has been developed
to express foreign sequences as either structural or non-structural
peptides. In our evaluation of the size of the insert that can be
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recombinants expressing either 35 or 62 amino acids of gag p24 as
amino-terminal extensions of the viral polyprotein are genetically
stable [16]. The upper size limit of inserts that is compatible with
genetic stability is 100 amino acids. We undertook a proof-of-
principle study to examine the immunogenicity, in mice, of a
CVB4/HIV recombinant that expresses 73 amino acids of the gag
p24 sequence. A comparative study of systemic gag p24-specific
immune responses after immunization via either an intraperitoneal
or an oral route was undertaken. This is the first report to
demonstrate that a live CVB4/HIV recombinant can induce
systemic gag p24-specific T cell responses after oral immunization.
Materials and Methods
Ethics Statement
All animal procedures were approved by the Institutional
Animal Care and Use Committee of the Wadsworth Center under
protocol 07-146. The Center is in compliance with the Principles
for Use of Animals, the Guide for the Care and Use of Laboratory
Animals, the Provisions of the Animal Welfare Act, and other
applicable laws and regulations.
Mice
Female BALB/c mice were purchased from The Jackson
Laboratory (Bar Harbor, ME) and immunized at the age of 6 to 8
weeks.
Construction of the CVB4/p24(733) recombinant
For the CVB4/p24(733) recombinant, the gag p24 sequence
(HXB2) corresponding to amino acids 3 to 75 was amplified by
PCR from a plasmid, HIV-gpt, and cloned into the CVB4
polyprotein cassette vector as previously described [16]. The gag
p24 sequence was positioned immediately after the initiator codon
of the VP4 sequence and was followed by a sequence encoding a
recognition site for the 3C protease (Fig. 1A). Clones were
screened initially by restriction enzyme analysis and verified by
DNA sequence analysis. RNA transcripts, synthesized from
recombinant cDNA clones with T3 RNA polymerase, were used
to transfect LLC-MK2(D) cells by electroporation. Virus was
harvested when cells exhibited 80–100% cytopathic effect (CPE).
Recombinant viruses were plaque-purified on LLC-MK2(D) cells.
To confirm the presence of the gag p24 sequence in the
recombinant virus, limited sequence analysis was done both on
viral RNA obtained from plaque-purified virus and on RNA
obtained from infected cells [19]. RNA samples were reverse-
transcribed using random primers and specific regions of the viral
cDNA were amplified by PCR and sequenced. Plaque-purified
virus was used to prepare a large-scale stock of the CVB4/p24(733)
recombinant in LLC-MK2(D) cells.
Intraperitoneal and oral immunizations of mice
Immunization was by intraperitoneal (IP) injection or by oral
gavage. Mice were immunized with either CVB4/p24(733) or the
parental CVB4. PBS-treated mice served as controls. For both IP
and oral immunizations, primary immune responses were assessed
10 to 14 days after administration of one dose (5610
4 pfu) of virus.
Secondary immune responses were assessed after the administra-
tion of an immunizing dose (5610
4 pfu) of virus and a boosting
dose (10
6 pfu) of virus. For IP immunizations, the boost was
administered 4 weeks after the immunizing dose, and spleens were
harvested at various time points (2, 7, 14, or 28 days) after the
boost. Maximal responses were observed 14 days after the boost.
For oral immunizations, the boost was administered two-to-four
weeks after the immunizing dose and spleens were harvested at
various time points (2, 7, 10, or 14 days) after the boost. Maximal
responses were observed 10 days after the boost. The difference in
the timing of administration of the boost reflects altered viral
replication after immunization via the intraperitoneal and oral
routes. Intraperitoneal immunization with either CVB4/p24(733)
or the parental CVB4 resulted in systemic infection and higher
viral replication while oral immunization caused a localized
infection and lower viral replication. Pathogenicity was monitored
by measurement of body weight, assessment of viral titers in
multiple organs, and evaluation of pancreatic tissue damage by
histology. For the histological studies, pancreatic tissues were fixed
with Bouin’s fixative (Sigma-Aldrich, St. Louis, Mo.), processed for
routine histology, and stained with hematoxylin and eosin.
Infectivity assays
Organs were weighed, and homogenates were prepared in PBS
using a Mini-BeadBeater (Biospec Products, Bartlesville, OK) and
1.0 mm zirconia/silica beads (Biospec Products, Bartlesville, OK).
Three organs per mouse - intestine, pancreas, and spleen - were
individually homogenized in 2 ml of PBS. For both Peyer’s
patches and mesenteric lymph nodes, 5 to 6 nodules per mouse
were collected and homogenized in 1.0 ml of PBS. Viral titers in
organ homogenates were measured using a standard plaque assay.
After oral delivery of virus, infectious virus was not detected by
plaque assay in any organ. For detection of low levels of infectious
virus early after oral delivery, HeLa cells, grown in 6-well plates,
were infected with 0.2 ml of organ homogenate and monitored for
the development of CPE.
Detection of anti-CVB4 antibodies by ELISA
ELISA Maxisorp (Nunc) 96 well plates were coated with
0.25 mg per well of purified coxsackievirus B4 in PBS and
incubated at 4uC overnight. Plates were washed three times with
PBS and 0.02%Tween 20 and blocked with PBS and 20% FBS for
2h ra t3 7 uC. Serial-fold dilutions of sera in PBS and 0.02%Tween
20 were loaded into duplicate wells. After incubation for 30 min at
37uC, plates were washed three times and peroxidase-conjugated
sheep anti-mouse antibody (Sigma) were added to the wells. Plates
were incubated for 30 min at 37uC and then washed three times.
The chromogenic substrate, 2,29-azino-bis-(3-benzthiazoline-6-
sulfonic acid) (Sigma), was added and optical densities were
measured using an ELISA plate reader Sunrise (Tecan) at 405 nm.
Sera from PBS-treated mice served as negative controls.
ELISPOT assay
The cytokine ELISPOT assay [20] was used to enumerate the
number of individual IFN-c secreting cells in spleens of
immunized mice. All anti-mouse antibodies were obtained from
BD Biosciences Pharmingen (San Diego, CA) or eBiosciences (San
Diego, CA). Briefly, 96-well nitrocellulose-based plates were
coated with rat anti-mouse IFN-c antibody at a final concentration
of 10 mg/ml. Plates were incubated overnight at 4u, washed with
PBS and blocked with 5% bovine serum albumin (BSA).
Splenocytes (2610
6 cells/well) were cultured in the presence of
an HIV-1 gag p24 peptide (2 mg/ml) for 24 hr at 37uC. The two
gag p24 peptides used in the study are p24(10–30) and p24(65–73).
The p24(10–30) peptide contains an H-2
d restricted T helper cell
epitope [21], while the p24(65–73) peptide contains an H-2
d
restricted CTL epitope [22]. Cultures were done in duplicate.
Negative controls consisted of splenocytes cultured with an
unrelated peptide (either from ovalbumin or from the circumspor-
ozoite protein of Plasmodium berghei) or no antigen. Positive
controls consisted of cells treated with either heat-inactivated
Oral Immunization with CVB/HIV
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6 PFU/well) or a combination of anti-mouse CD3
antibody and anti-mouse CD28 antibody. After washing with PBS,
biotinylated rat anti-mouse IFN-c antibody was added to each
well. After washing with PBS, the bound biotinylated antibody was
detected using a streptavidin-alkaline phosphatase conjugate. The
number of spots on each filter was counted using a CTL-
ImmunoSpot S5 UV Analyzer (Cellular Technology Ltd, Shaker
Heights, OH) and CTL ImmunoSpot software (Cellular Tech-
nology Ltd). The negative controls for the IFN-c ELISPOT assay
allowed us to define a negative response as less than 50 spot-
forming cells (SFC) per well.
Multiparameter flow cytometry
HIV-1 gag p24-specific T cell responses in mice immunized
with CVB4/p24(733) were assessed using a five-color intracellular
staining assay. Splenocytes (10
6 cells/well) were cultured with
either of the two HIV-1 gag p24 peptides (2 mg/ml), p24(10–30) or
p24(65–73), for 1 hr at 37uC. Splenocytes from mice immunized
with the parental virus, CVB4, and cultured with the HIV-1 gag
p24 peptides, served as the vector control. Negative controls
consisted of splenocytes from mice immunized with either CVB4/
p24(733) or CVB4 and cultured with an unrelated peptide (either
from ovalbumin or from the circumsporozoite protein of
Plasmodium berghei). Positive controls consisted of splenocytes
treated with anti-CD3 (5 mg/ml) and anti-CD28 (2 mg/ml)
antibodies.
The BD Cytofix/Cytoperm Plus kit (BD Biosciences, San
Diego, CA) was used for inhibition of intracellular protein
transport and for the fixation and permeabilization of cells. BD
GolgiPlug (0.5 ml/ml), a protein transport inhibitor containing
Figure 1. Construction and biological properties of the CVB4/p24(733) recombinant. (A) Construction of the CVB4/p24(733) recombinant.
The top line shows the two T cell epitopes of gag p24 that are contained within CVB4/p24(733). The middle line depicts the genetic organization of
the CVB4 genome and shows the insertion site for the gag p24 sequence, between the 59 untranslated region (UTR) and the VP4 sequence. The
bottom line shows the 73 amino acids (residues 3 to 75) of gag p24 (HXB2) in the extended polyprotein sequence of CVB4/p24(733). The H-2
d
restricted T cell epitopes are indicated along with the recognition sequence for the CVB4 3C protease. (B) The CVB4/p24(733) recombinant shares the
thermostable phenotype of its parental virus, CVB4. Samples containing 10
7 pfu of virus were heated at 44uC for different time intervals, and the
residual infectivity was determined by plaque assay. Experiments were done twice and both inactivation profiles for each virus are shown. m, D:
CVB4/p24(733);N, #: CVB4. (C) The CVB4/p24(733) recombinant is replication-competent. The replication of CVB4/p24(733) and CVB4 in LLC-MK2(D)
cells was assessed under single-step conditions. Each experiment was done twice and both growth curves for each virus are shown. m, D: CVB4/
p24(733);N, #: CVB4.
doi:10.1371/journal.pone.0012499.g001
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for an additional 4 to 5 hr at 37uC. The following rat anti-mouse
monoclonal antibodies (BD Biosciences Pharmingen, San Diego,
CA) were used: anti-CD4-PE-Cy7, anti-CD8-PerCP, anti-IFN-c-
FITC, anti-IL-2-PE, and anti-TNF-a-APC. Splenocytes were
incubated initially with the anti-CD4 and anti-CD8 antibodies on
ice for 30 min. Cells were then fixed and permeabilized with the
Cytofix/Cytoperm solution. After washing with the Perm/Wash
buffer, cells were incubated with the anti-IFN-c, anti-TNF-a, and
anti-IL-2 antibodies on ice for 30 min. After washing in PBS, cells
were fixed in 1% paraformaldehyde and analyzed by flow
cytometry using the BD FACSAria II (BD Biosciences, San Jose,
CA). Gag p24-specific T cell frequencies in CVB4/p24(733)
immunized mice were calculated as follows: [T cell freq CVB4/
p24(733)gag p24 peptide – T cell freq CVB4/p24(733)unrelated peptide]-
[T cell freq CVB4gag p24 peptide – T cell freq CVB4unrelated peptide].
Results
The CVB4/p24(733) recombinant retains the physical and
biological characteristics of the parental CVB4 vector
The CVB4/p24(733) recombinant contains an insert of 243
nucleotides of which 219 nucleotides are from the gag p24
sequence (Fig. 1A). Because a longer CVB4 genome could alter the
physical packaging of RNA and capsid proteins, thereby affecting
viral stability, we evaluated the physical stability of the
recombinant. The thermal stability of CVB4/p24(733) was
compared to that of the parental virus, CVB4 (Fig. 1B). The
parental virus is thermostable: after 1 hr at 44u, infectivity
decreased an average of 40-fold. The CVB4/p24(733) recombi-
nant was more rapidly inactivated than the parental vector during
the first 30 min of inactivation. However, after 1 hr of
inactivation, overall infectivity decreased an average of 25-fold
and was thus similar to that observed for the parental virus. The
CVB4/p24(733) recombinant shares the thermostable phenotype
of its parental virus. To determine whether the insertion of the gag
p24 sequence into the CVB4 genome affected viral replication, we
analyzed the growth kinetics of CVB4/p24(733) in cell culture,
under single-step conditions (Fig. 1C). After 16 hr, CVB4/
p24(733) replicated as well as the parental vector. However, the
kinetics of replication differed. During the exponential phase of
growth, the recombinant replicated to higher titers than the CVB4
vector. We also evaluated the genetic stability of the CVB4/
p24(733) recombinant after multiple passages in cell culture, at low
multiplicities. Viral sequences from infected cells were reverse-
transcribed, amplified by PCR, and sequenced. Deletion products
were not observed during amplification (data not shown). After
seven passages in cell culture, the recombinant retained the 219
nucleotides of the gag p24 sequence. The CVB4/p24(733)
recombinant is thus physically stable, replication-competent, and
genetically stable.
Pathogenicity is influenced by the route of delivery
We assessed whether the gag p24 insert affects viral pathoge-
nicity by monitoring CVB4/p24(733) infected mice for visible signs
of infection, changes in body weight, viral load in target organs,
and pancreatic tissue damage. BALB/c mice infected with CVB4/
p24(733) either orally or intraperitoneally appeared healthy,
showed no visible signs of infection and gained weight (Fig. 2A).
We measured viral loads by plaque assay in organs harvested 2
days after infection with CVB4/p24(733) because viral loads in
pancreatic tissues are maximal 2 days after infection via the
Figure 2. Replication of the CVB4/p24(733) recombinant in BALB/c mice. (A) Mice infected with CVB4/p24(733) gained weight. Mice (n=3)
were infected intraperitoneally with CVB4/p24(733)( m) or CVB4 (%) or were mock-infected with PBS (N), and body weights were measured at various
times after infection. (B) Intraperitoneal delivery of CVB4/p24(733) resulted in systemic infection, while oral delivery did not result in systemic
infection. Mice (n=3) were infected with 5610
4 pfu administered intraperitoneally, 5610
4 pfu administered orally, or 10
6 pfu administered orally.
Pancreas, spleen, and intestine were harvested from each mouse at 2 dpi, and organ homogenates were tested for viral infectivity by plaque assay.
Dashed lines indicate the limit of detection of infectious virus. ND: not detected.
doi:10.1371/journal.pone.0012499.g002
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was detected in pancreas, spleen, and intestine of BALB/c mice
infected intraperitoneally with a dose of 5610
4 pfu of CVB4/
p24(733) (Fig. 2B). Of the three organs, viral titers were highest in
pancreas. In contrast, infectious virus was not detected by plaque
assay in any of the organs of mice infected orally with either the
same dose (5610
4 pfu) or a higher dose (10
6 pfu) of CVB4/
p24(733) (Fig. 2B). The data for the higher inoculum were
confirmed by monitoring the development of CPE in HeLa cells
infected with organ homogenates (Table 1). We next investigated
whether infectious virus could be detected in mice earlier than 2
days after oral delivery of the higher dose of 10
6 pfu of CVB4/
p24(733).
We reasoned that low titers of infectious virus might be below
the level of detection of the plaque assay and decided to monitor
infectivity by the development of CPE in HeLa cells. While
infectious virus was detected in the intestine, for all infected mice,
from 8 to 24 hr after infection, infectious virus was not detected in
spleen or pancreas (Table 1). Infectious virus was absent from the
mesenteric lymph nodes at 8 and 16 hr after infection and was
detected in only one sample at 24 hr after infection. Infectious
virus was also absent in all samples of Peyer’s patches at 8 hr after
infection and was detected in one sample at 16 hr and in one
sample at 24 hr after infection. The combined data indicate that
after oral delivery, the CVB4/p24(733) recombinant induces a
short-lived, localized infection of the gut without systemic spread.
While infected mice showed no visible signs of disease,
histological assessment of pancreatic tissues revealed a transient
pancreatitis in mice that had been infected by the intraperitoneal
route although not by the oral route (Fig. 3). BALB/c mice
infected intraperitoneally with 5610
4 pfu of CVB4/p24(733)
developed a transient pancreatitis from 4 dpi to 7 dpi (Fig. 3,
panels a and b). Pancreatitis affected approximately 50% of the
organ and was characterized by exocrine tissue loss, focal
inflammation, and edema. By 14 dpi, pancreatitis had resolved
and the exocrine tissues showed complete recovery (data not
shown) similar to that observed in mice infected with the parental
CVB4 vector [24]. In marked contrast, BALB/c mice infected
orally with 5610
4 pfu or 10
6 pfu of CVB4/p24(733) did not
develop pancreatitis (Fig. 3, panels c–f). Pancreatic acinar cells
were well-granulated and intact and showed no evidence of
damage.
Evaluation of the antigenicity of the CVB4/p24(733)
recombinant and the CVB4 vector
The CVB4/p24(733) recombinant is designed to express the gag
p24 sequence as a non-structural protein and is expected to retain
the antigenicity of the parental CVB4 vector. To test whether the
antigenicity of the recombinant is similar to the parental vector,
mice were immunized intraperitoneally with either CVB4/
p24(733) or CVB4. Sera harvested 10 days after either primary
or secondary immunization were assayed by ELISA for antibodies
that bound to the purified CVB4 vector. Antibody titer is defined
as the reciprocal of the lowest serum dilution whose absorbance at
405 nm is greater than four-fold the absorbance of the
corresponding dilution of control sera. Primary anti-CVB4 titers
were similar in mice immunized with either CVB4 or CVB4/
p24(733) (Fig. 4). Both groups of immunized mice showed an
anamnestic response to vector antigens because anti-CVB4 titers
increased after immunization with more than one dose of virus
(Fig. 4). Furthermore, the anamnestic response of mice immunized
with CVB4/p24(733) is greater than that of mice immunized with
CVB4. It is unclear why the recall response to vector antigens is
greater in mice immunized with CVB4/p24(733). Given that
CVB4/p24(733) replicated to higher titers than CVB4 during the
exponential phase of growth (Fig. 1C), a possible explanation is
that the recombinant replicates to higher titers than the vector
in vivo. Increased viral replication is expected to generate a greater
amount of vector antigens, capable of inducing a more vigorous
antibody response.
Assessment of cytokine production from splenocytes of
mice immunized with CVB4/p24(733)
Splenocytes from immunized mice were stimulated with either
of two gag p24 peptides, p24(10–30) and p24(65–73), each of
which contains an H-2
d restricted T cell epitope present in CVB4/
p24(733), and IFN-c production was monitored by the ELISPOT
assay. Primary immune responses were monitored after adminis-
tration of one dose of CVB4/p24(733), whereas secondary
immune responses were monitored after administration of two
doses of CVB4/p24(733). Splenocytes from mice immunized
intraperitoneally with one dose (5610
4 pfu) of the recombinant
produced IFN-c in response to stimulation with the p24(65–73)
peptide but not in response to stimulation with the p24(10–30)
peptide (Fig. 5). Splenocytes from mice immunized orally with one
dose (5610
4 pfu) of the recombinant failed to produce IFN-c in
response to stimulation with either of the gag p24 peptides. Oral
immunization with the higher dose (10
6 pfu) of CVB4/p24(733)
also failed to elicit primary immune responses against gag p24.
Unlike primary immune responses, secondary immune responses
to the p24(65–73) peptide were detected after either intraperito-
neal or oral immunization. A boost effect was observed after
immunization by the oral route but not after immunization by the
intraperitoneal route. The data suggest that one intraperitoneal
dose of the recombinant is sufficient to induce strong primary gag
p24-specific immune responses while two oral doses of the
recombinant are needed to induce strong secondary immune
responses.
Secondary immune responses to gag p24 were also evaluated in
mice pre-immunized with the parental vector, CVB4. Because the
normal route of transmission for coxsackieviruses is the oral route,
mice were pre-immunized orally with CVB4. To verify that mice
developed immunity to the CVB4 vector, serum samples, collected
7 days after the pre-immunization, were assayed for anti-CVB4
antibodies by ELISA. Mice pre-immunized orally had high
antibody titers (ranging from 500 to1,000) against the CVB4
Table 1. The CVB4/p24(733) recombinant induced a localized
infection in the gut after oral delivery.
No. of organs containing infectious virus
Time p.i.
(hrs) Intestine PP* MLN
# Spleen Pancreas
8 3/3 0/3 0/3 0/3 0/3
16 3/3 1/3 0/3 0/3 0/3
24 3/3 1/3 1/3 0/3 0/3
48 0/3 ND ND 0/3 0/3
*Peyer’s patches (5–6 in each sample);
# mesenteric lymph nodes (5–6 in each sample). Organ homogenates (0.2 ml)
were used to infect HeLa cells and infectivity was evaluated by the
development of CPE. ND, not done.
doi:10.1371/journal.pone.0012499.t001
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weeks later and boosted orally with the CVB4/p24(733)
recombinant. As was observed with naı ¨ve mice immunized with
CVB4/p24(733), CVB4-immune mice immunized with CVB4/
p24(733) generated gag p24-specific immune responses. IFN-c
production was detected by splenocytes stimulated with the
p24(65–73) peptide (Fig. 5).
Splenic CD4 and CD8 T cells from mice immunized with
CVB4/p24(733) produced cytokines after stimulation with
HIV-1 gag p24 peptides
Splenocytes from immunized mice were stimulated with either
of the two gag p24 peptides, p24(10–30) and p24(65–73), and T
cells producing TNF-a, IL-2, or IFN-c were identified by
multiparameter flow cytometry. The functionality of gag p24-
specific T lymphocyte responses was assessed using Boolean gating
and FlowJo software (TreeStar Inc., Ashland, OR).
A statistical analysis of the frequency of T cells producing
cytokines in response to gag p24 peptides reveals that gag p24-
specific T cell responses are similar after intraperitoneal
immunization with one or two doses of CVB4/p24(733) (Fig. 6A
and 6B). The one exception was IFN-c production by CD8 T cells
in response to the p24 (65–73) peptide which was stronger after
immunization with one dose of the recombinant. In comparing T
cell responses after immunization via different routes, we observed
that the frequencies of T cells producing cytokines in response to
gag p24 peptides were similar after intraperitoneal or oral
immunization (Fig. 6B and 6C). Again, the only exception was
IFN-c production by CD8 T cells in response to the p24 (65–73)
peptide which was stronger after oral immunization. The
intracellular staining studies support the results of the ELISPOT
studies and suggest that one intraperitoneal dose of CVB4/
p24(733) is sufficient to induce strong primary gag p24-specific
immune responses while two oral doses of the recombinant are
needed to induce strong secondary immune responses.
The functionality of gag p24-specific T cell responses was
assessed using Boolean gating and FlowJo software, and the data is
depicted as pie charts in Fig. 6. Polyfunctional T cells were
detected after intraperitoneal immunization but not after oral
immunization. Furthermore, immunization with one dose of the
recombinant yielded polyfunctional T cells that responded to the
p24(65–73) peptide but not to the p24(10–30) peptide (Fig. 6A,
pie-charts). In a representative experiment, of the CD4 T cells
Figure 3. Transient pancreatitis develops after intraperitoneal administration of CVB4/p24(733) but it does not develop after oral
administration. Mice (n=4) were infected with 5610
4 pfu administered intraperitoneally, 5610
4 pfu administered orally, or 10
6 pfu administered
orally. The pancreas was harvested from 2 mice at 4 dpi and from 2 mice at 7 dpi. Tissues were processed for routine histology and stained with
hematoxylin and eosin. Representative sections are shown. (a) 4 dpi, IP infection with 5610
4 pfu, depicting pancreatitis; (b) 7 dpi, IP infection with
5610
4 pfu, depicting pancreatitis; (c) 4 dpi, oral infection with 5610
4 pfu, depicting a healthy, intact pancreas; (d) 7 dpi, oral infection with
5610
4 pfu, depicting a healthy, intact pancreas; (e) 4 dpi, oral infection with a higher dose,10
6 pfu, depicting a healthy, intact pancreas; (f) 7 dpi, oral
infection with a higher dose,10
6 pfu, depicting a healthy, intact pancreas. A, acinus (core structure of the exocrine pancreas consisting of 8-12 acinar
cells; IL, islet of Langerhans; in, inflammatory infiltrates. Original magnification, 6250. The scale bar is 25 mm.
doi:10.1371/journal.pone.0012499.g003
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recombinant, 38% produced IL-2 alone, 40% produced IFN-c
alone, and 21% produced both IL-2 and IFN-c. Of the CD8 T
cells responding to the p24(65–73) peptide, 31% produced IL-2
alone, 37% produced IFN-c alone, and 32% produced both IL-2
and IFN-c. While immunization with one dose of the recombinant
yielded polyfunctional T cells that responded to the p24(65–73)
peptide, immunization with two doses of the recombinant resulted
in polyfunctional T cells that responded to the p24(10–30) peptide
(Fig. 6B, pie-charts). In a representative experiment, of the CD4 T
cells responding to the p24(10–30) peptide after two doses of the
recombinant, 27% produced IL-2 alone, 41% produced IFN-c
alone, 26% produced TNF-a alone, and 6% produced dual
combinations of cytokines. Of the CD8 T cells responding to the
p24(10–30), 36% produced IL-2 alone, 28% produced IFN-c
alone, 28% produced TNF- a alone, and 9% produced both IL-2
and IFN-c. The data indicate that while the frequency of T cells
producing cytokines in response to gag p24 peptides are similar
after intraperitoneal immunization with one or two doses of
CVB4/p24(733), the quality of the responses differ.
The data from the ELISPOT assays show that splenocytes from
mice immunized with the CVB4/p24(733) recombinant produced
IFN-c in response to the immunodominant CTL epitope, p24(65–
73), but not to the non-dominant T helper cell epitope, p24(10–30)
while the data from the flow cytometric studies show that splenic T
cells from immunized mice produced cytokines in response to both
gag p24 peptides. A possible explanation for this observation is
that the p24(10–30) peptide induced lower levels of cytokine per
cell than the p24(65–73) peptide. The lower response to the
p24(10–30) peptide was detected by intracellular staining because
the assay concentrates cytokines in each cell.
Discussion
We showed that a live recombinant, CVB4/p24(733), express-
ing 73 residues of gag p24, retained the physical, biological, and
antigenic characteristics of the parental vector. Oral immunization
with the CVB4 recombinant was safe and resulted in the induction
of systemic HIV-specific T cell responses. Furthermore, pre-
existing vector immunity did not preclude the development of gag
p24-specific T cell responses.
The gag p24 sequence within the CVB4/p24(733) recombinant
contains two well-characterized H-2
d restricted T cell epitopes, an
immunodominant CTL epitope and a non-dominant T helper cell
epitope [21,22]. The CVB4/p24(733) recombinant was designed
to express the gag p24 sequence as an intracellular, non-structural
peptide which would be processed through the MHC class I
pathway, thereby allowing presentation of the p24 CTL peptide to
CD8 T cells. Uptake of extracellular antigens from cellular debris
by antigen presenting cells (APCs) is expected to allow processing
through the MHC class II pathway, thereby allowing presentation
of the p24 T helper cell epitope to CD4 T cells [25]. In addition,
cross-presentation of extracellular antigens by APCs is expected to
amplify presentation of the p24 CTL peptide to CD8 T cells. Data
from the five-color intracellular assay showed that CD8 T cells
from mice immunized with CVB4/p24(733) did, in fact, produce
cytokines after in vitro stimulation with the p24 CTL peptide, while
CD4 T cells produced cytokines after in vitro stimulation with the
p24 T helper cell peptide. The data also show that CD8 T cells
produce cytokines after stimulation with the p24 T helper cell
peptide while CD4 T cells produce cytokines after stimulation with
the p24 CTL epitope. The reasons for these observations are
unclear. A potential explanation of the CD8 T cell response after
stimulation with the p24(10–30) peptide is that a sequence within
this T helper cell peptide is also able to stimulate CD8 T cells.
We also evaluated the effect of immunizing mice with the
CVB4/p24(733) recombinant using different doses and different
routes of delivery. We showed that a boost effect was observed
after oral immunization but not after intraperitoneal immuniza-
tion. In addition, immunization via the oral route or the
intraperitoneal route resulted in similar frequencies of gag p24-
specific T cells. The one exception was that oral but not
intraperitoneal immunization induced CD8 T cells that produced
IFN-c in response to the p24 CTL peptide.
While we have been working on a live CVB4-based HIV
vaccine platform, other groups have been developing polioviruses
as replicating and non-replicating vaccine vectors. The initial
study to show that picornaviruses could be developed as vaccine
vectors was done using poliovirus [26]. The poliovirus recombi-
nants induced antibody responses [26] and CTL responses [27]
against the inserted sequences. Replication competent poliovirus
recombinants, based on the Sabin poliovirus vaccine strains, have
also been constructed to express the entire SIV genome in discrete,
overlapping fragments [18]. Macaques immunized with the
poliovirus-SIV vaccine cocktails showed some protection after
challenge with SIVmac251 [28]. A non-replicating poliovirus
replicon system has also been developed to express HIV-1 and
Figure 4. Mice immunized with either the CVB4 vector or the
CVB4/p24(733) recombinant develop an anamnestic response
to vector antigens. Mice (n=3) were immunized via the intraperi-
toneal route with either CVB4 or CVB4/p24(733). Sera from mice
immunized with one dose of virus (primary responses) or three doses of
virus (secondary responses) were tested for anti-CVB4 antibodies by
ELISA. Primary anti-CVB4 titers were similar in mice immunized with
either CVB4 (open circles) or CVB4/p24(733) (open squares). Secondary
anti-CVB4 titers were greater in mice immunized with CVB4/p24(733)
(filled squares) than in mice immunized with CVB4 (filled circles).
Statistical analysis was done using a one-way ANOVA.
doi:10.1371/journal.pone.0012499.g004
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in macaques. A limitation of the live poliovirus vector system is
that immunogenicity studies must be done in macaques because
poliovirus does not replicate in wild-type mice. A major advantage
of a CVB4-based HIV vaccine platform is that extensive
immunogenicity studies can be done in mice. Vaccination
strategies for the CVB4/HIV recombinants can be tested and
optimized in mice prior to evaluation in macaques. Another
picornavirus that has been developed to express HIV-1 sequences
is the human rhinovirus 14. A combinatorial approach has been
used to construct libraries of rhinoviruses expressing an HIV-1
gp41 epitope [30]. Recombinant rhinoviruses induced modest
levels of HIV-1 neutralizing antibodies in guinea pigs.
For any vector system that is under development for use as an
HIV vaccine, a key question is whether pre-existing vector
immunity will inhibit the ability of the recombinant vaccine to
induce HIV-specific T and B cell responses [5,31]. This concern is
particularly relevant for a coxsackievirus vector because coxsack-
ieviruses are ubiquitous in the human population [32]. We have
shown that mice immunized via the intraperitoneal route with the
avirulent parental CVB4 vector, were protected when subsequent-
ly challenged with a virulent CVB4-V variant [16] indicating that
pre-existing immunity has an impact on second exposure. Data
from the present study further support this observation since mice
immunized with a second dose of the CVB4 recombinant,
delivered via the intraperitoneal route, did not show increased
gag p24-specific immune responses. However, immunization via
the oral route was able to by-pass pre-existing immune responses
since oral immunization with two doses of the CVB4 recombinant
resulted in increased immune responses. We also addressed
whether oral immunization with the CVB4 recombinant was able
to bypass pre-existing vector immunity. We showed, in a pilot
study, that oral immunization with the CVB4/p24(733) recombi-
nant induced gag p24-specific systemic immune responses in mice
with pre-existing vector immunity, and these responses were
comparable to responses in vector-naı ¨ve mice. The data support
the conclusion that oral immunization with the recombinant
bypasses pre-existing immunity. Vaccine vectors such as adeno-
virus [33,34] and Listeria monocytogenes [35] have also been
shown to bypass pre-existing immunity when administered via the
oral or nasal routes.
Another important issue in the use of recombinant viruses as
vaccines is safety. Historically, live attenuated, replicating viruses
have provided the most effective protection against disease [5].
By contrast, inactivated or subunit vaccines induce immunity of
more limited duration. A driving factor in the development of
inactivated or subunit vaccines is safety. Clearly, there is a trade-
off between safety and efficacy in developing a viral vaccine. In
humans, most infections with the group B coxsackieviruses are
asymptomatic [36]. When symptomatic infections occur, the
group B viruses cause mild illnesses of the upper respiratory tract,
the gastrointestinal tract, and the skin. Rare serious manifesta-
tions of acute CVB infection include aseptic meningitis,
myocarditis, and pericarditis. A few case reports and studies of
animal models suggest links between CVB infections and chronic
diseases of the heart [37] and pancreas [38,39]. Data from studies
of CVB pathogenesis indicate that immunomodulatory approach-
es are beneficial in treating both acute and chronic stages of
disease [40,41]. Should a CVB4-based vaccine be developed,
then increased research efforts will be needed to identify
Figure 5. Gag p24-specific IFN-c production by splenocytes after IP or oral immunization with CVB4/p24(733). Primary (Pri) and
secondary (Sec) immune responses were monitored using an IFN-c ELISPOT assay. The immunizing dose used in these studies was 5610
4 pfu, except
in one study in which a higher dose,10
6 pfu, was used to evaluate primary responses after oral delivery. IFN-c production in response to p24(10–30) is
indicated by open symbols while IFN-c production in response to p24(65–73) is indicated by filled symbols. Each symbol represents the result from
one mouse. Negative controls defined a negative response as less than 50 SFC per well, indicated by a dashed line. Gag p24(65–73)-specific primary
and secondary immune responses were observed after IP immunization, while gag p24(65–73)-specific secondary immune responses were observed
after oral immunization of CVB4 naı ¨ve and CVB4 immune mice. Statistical analysis was done using the t-test.
doi:10.1371/journal.pone.0012499.g005
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PLoS ONE | www.plosone.org 8 September 2010 | Volume 5 | Issue 9 | e12499Figure 6. T cells from mice immunized either intraperitoneally or orally with CVB4/p24(733) produce cytokines in response to gag
p24 peptides. Splenic CD4 and CD8 T cells producing TNF-a, IL-2, or IFN-c in response to p24(65–73) or p24(10–30) were identified by
multiparameter flow cytometry. (A) Primary immune responses after immunization via the intraperitoneal route. (B) Secondary immune responses
after immunization via the intraperitoneal route. (C) Secondary immune responses after immunization via the oral route. Each symbol represents the
results from one experiment using splenocytes pooled from 3 mice. Experiments were done a total of three or four times and all of the data are
shown here. Mean values are indicated by horizontal bars. Flow cytometric analysis was performed after gating on CD4 or CD8 T cells. The T cell
frequency indicates the percentage of CD4 or CD8 T cells that is responding to the gag p24 peptides. T cell frequencies after IP immunization with
one or two doses of virus were similar. The one exception is indicated by a closed arrowhead (P,0.05). T cell frequencies after IP or oral immunization
with two doses of virus were also similar. The one exception is indicated by an open arrowhead (P,0.05). Statistical analysis was done using a one-
way ANOVA. The functionality of gag p24-specific T cell responses was assessed using Boolean gating and FlowJo software, and the data is shown in
pie charts. Polyfunctional T cells were detected after IP immunization but not after oral immunization.
doi:10.1371/journal.pone.0012499.g006
Oral Immunization with CVB/HIV
PLoS ONE | www.plosone.org 9 September 2010 | Volume 5 | Issue 9 | e12499appropriate immune-based therapies for treating reversion
events.
The CVB4 vector used to construct the CVB4/p24(733)
recombinant has been studied extensively, and several reports
show that the CVB4 vector induces a transient pancreatitis in
mice, after infection by the intraperitoneal route [23,24,36,38,42].
The present report shows that the pathogenicity of the CVB4/
p24(733) recombinant is influenced by the route of infection.
Administration of the CVB4/p24(733) recombinant via the
intraperitoneal route resulted in a transient pancreatitis, similar
to that observed with the parental CVB4. However, administra-
tion of the recombinant via the oral route resulted in a short-lived,
localized infection of the gut, without systemic spread. Mice
immunized orally with CVB4/p24(733) gained weight, were well-
groomed, and appeared to be healthy. Pancreatic tissues from
mice immunized orally showed no evidence of pancreatitis.
The present study shows that oral immunization with a CVB4/
HIV recombinant induced systemic gag p24-specific T cell
responses. Ongoing studies are evaluating the mucosal gag p24-
specific immune responses that develop after oral immunization
with the CVB4 recombinant. As the search continues for new HIV
vaccine strategies capable of inducing systemic and mucosal
immune responses, the present proof-of-principle study suggests
that live CVB4/HIV recombinants are worth exploring as new
vaccine candidates.
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